As treatment for high-bleeding-risk (HBR) patients with acute or chronic coronary syndromes, the Cobra PzF nanocoated coronary stent followed by 2 weeks of dual antiplatelet therapy (DAPT) did not reduce bleeding and failed to demonstrate noninferiority to standard drug-eluting stents (DES) with 3 to 6 months of DAPT with respect to thrombotic events, according to study results presented Saturday at the TCT Connect virtual conference.